# A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults

> **NCT05721287** · PHASE1 · COMPLETED · sponsor: **Sparian Biosciences, Inc** · enrollment: 48 (actual)

## Conditions studied

- Pain
- Acute Pain

## Interventions

- **DRUG:** SBS-1000
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05721287
- **Lead sponsor:** Sparian Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-30
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-08-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05721287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05721287, "A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05721287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*